Compare Enveric Biosciences Inc (ENVB) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Norwegian Cruise Line Holdings Ltd trades at $15.44 (market cap $7.11B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 1045.6× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 22,683,268). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| ENVB | NCLH | |
|---|---|---|
Market Cap | $6.80M | $7.11B |
Volume | 64,867 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $10.80 | $25.02 |
52-Week Low | $1.27 | $14.12 |
Typical Hold Time | 14 Days | 68 Days |
Enterprise Value | -$1.49M | $21.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Norwegian Cruise Line Holdings (NCLH) trades at $15.05, down 2.97% on the day, with a neutral technical signal and bearish moving average trend. The company reported strong earnings beats in recent quarters, with Q3 2026 expected to exceed guidance at $0.914 EPS. Fundamentals show robust revenue growth to $9.83B in 2025, though net income margin compressed to 4.3%. Recent news highlights yield pressure and a $950M senior notes offering.
NCLH presents a mixed outlook: valuation appears attractive with a P/E of 9.39 and analyst consensus target of $20.86, implying upside. However, high debt levels, net yield pressures, and volatile cash flows pose risks. The stock offers potential for recovery if operational improvements and pricing strategies stabilize profitability through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
